A5074592131- Botulinum Toxin and Related Neurological Disorders
- SARS-CoV-2 and COVID-19 Research
- Biochemical effects in animals
- Circadian rhythm and melatonin
- Sleep and related disorders
- Viral Infections and Immunology Research
- Neurological disorders and treatments
- Sleep and Wakefulness Research
- Toxic Organic Pollutants Impact
- Per- and polyfluoroalkyl substances research
- RNA regulation and disease
- Atmospheric chemistry and aerosols
- Endoplasmic Reticulum Stress and Disease
- Parkinson's Disease Mechanisms and Treatments
- Bacterial Infections and Vaccines
Takeda (Japan)
2018-2023
Kyoto University
2003-2005
Abstract Continuous, objective monitoring of motor signs and symptoms may help improve tracking disease progression treatment response in Parkinson’s (PD). This study assessed the analytical clinical validity multi-sensor smartwatch measurements hospitalized home-based settings (96 patients with PD; mean wear time 19 h/day) using a twice-daily virtual examination (VME) at times representing medication OFF/ON states. Digital measurement performance was better during inpatient assessments for...
A single mutation (C96Y) in the Ins2 gene, which disrupts A7-B7 disulfide bond, causes diabetic phenotype Akita mice. We biochemically analyzed conformation of wild-type and mutant recombinant proinsulins. Gel filtration chromatography dynamic light scattering revealed that apparent size proinsulin molecules was significantly larger than proinsulin, even absence intermolecular bonds. Titration with a hydrophobic probe, 1-anilinonaphthalene-8-sulfonate, demonstrated more wild type. In...
Background: With the goal of global eradication poliomyelitis due to wild-type viruses within sight, WHO now recommends that infants receive at least one dose trivalent inactivated poliovirus vaccine (IPV) with bivalent OPV (types 1 and 3) replacing OPV. Limited manufacturing capacity new regulations on manufacturers' use is driving development IPV based attenuated Sabin type polioviruses. Takeda are developing a Sabin-based (sIPV) augment supply.Methods: This study was performed evaluate...
The purpose is to evaluate the effect and safety of ramelteon 8 mg/day for weeks in treatment insomnia patients with concurrent depression an exploratory manner. This phase 4, open-label, study included outpatients aged 20 < 65 years sleep-onset major depressive disorder taking stable antidepressant medication. Following a 1-week run-in, 26 eligible received plus their usual antidepressants weeks. Outcomes sleep parameters measured by actigraphy diary, 3-Dimensional Sleep Scale (3DSS),...